Aprecia selects InVentiv to commercialize its 3-D printing tech platform

Aprecia selects InVentiv to commercialize its 3-D printing tech

Aprecia Pharmaceuticals has selected inVentiv Health to sell and market its three-dimensional printing technology to create fast-melt pharmaceutical treatments. 

This partnership will look to launch Aprecia’s proprietary ZipDose product platform, which uses three-dimensional printing technology to create fast-melt products. Aprecia claims the platform allows the production of sponge-like wafer forms of existing medicines. 

Under the terms of the agreement, inVentiv will partner with Aprecia as its exclusive provider of commercialization services in exchange for a negotiated royalty from future sales. 

Michael Griffith, EVP of inVentiv, told us Aprecia has the rights to market four reformulated therapies, which both companies expect to be approved. 

We think approval is highly likely…as the drugs themselves are already approved – question is the dosage form and does it deliver with its bioavailability,” he said. 

Griffith also explained how the commercialization will work from start to finish. “At the beginning it’s the strategy around medical communications to set pricing, to condition clinicians – ads and PR – forming a sales force, develop all of the collateral around that force, and then to work with pharmacies to increase compliance,” Griffith said. 

He added that inVentiv is looking “to a do a lot of these types of deals for the commercialization of drugs and devices. This is one example of co-development” where the companies will share risk and reward, he said. 

Manufacturing platform 

The manufacturing platform from Aprecia does not rely on compression or other processes so the ZipDose formulations can achieve high doses (50 – 1,000mg) without slowing down the speed at which this new form dissolves in the mouth.  In addition, the new platform allows for a wider range of taste-masking and time-release technologies than were previously possible, according to Aprecia. The company has filed patent applications to protect its proprietary manufacturing system through 2033. 

Aprecia expects to file its first New Drug Application with the US FDA in the second half of 2014, and expects approval of the product in the second half of 2015, though the company has yet to reveal what the product is. 

Related News

A model of the HIV protease printed on a 3D printer at the Scripps Institute

NIH 3D printer project to allow public to create drug models

Biotech CEL-SCI claims levels of enrolment in Ph III trial dropped after inVentiv acquired CRO Pharmanet

inVentiv: $50m breach of contract claim 'meritless' as trial looms

3D printing firm buys old, new Forest plant

3D pill printing firm Aprecia leases Forest Labs site as production hub

inVentiv expands NIS services to help stem confusion on new EU trials regulation

inVentiv expands NIS services to help stem confusion on new EU trials regulation

inVentiv Seeks to Accelerate Recruitment of Investigators

inVentiv Seeks to Accelerate Recruitment of Investigators with Partnership

inVentiv Partnership Aims to Bring Top Biosimilars to Market

inVentiv Partnership Aims to Bring Top Biosimilars to Market

InVentiv pushes into Japan again, offering consulting this time

InVentiv pushes into Japan again, offering consulting this time

Related Products

See more related products